Medicare Enrolled
Dr. Robert Reilly, DO
Hematology & Oncology · Langhorne, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Reilly from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reilly?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reilly
Dr. Robert Reilly is a hematology & oncology specialist in Langhorne, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Reilly performed 49,966 Medicare services across 1,722 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reilly received a total of $14,546 from 87 pharmaceutical and/or device companies across 752 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reilly is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in PA
$14,546 industry payments
Medicare Practice Summary
Medicare Utilization ↗49,966
Medicare services
Top 12% in PA for hematology & oncology
1,722
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,630 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
20,820 | $2 | $21 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,850 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 7,680 | $18 | $68 |
| Iron infusion (Monoferric) | 3,800 | $16 | $73 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,516 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,362 | $8 | $35 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
976 | $8 | $19 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
911 | $70 | $148 |
| Anti-nausea injection (Aloxi/palonosetron) | 900 | $1 | $122 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
527 | $13 | $105 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
325 | $12 | $93 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
284 | $101 | $224 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
214 | $113 | $686 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
162 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
131 | $54 | $304 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
105 | $27 | $141 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
104 | $25 | $152 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
90 | $1 | $9 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
52 | $66 | $157 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
33 | $39 | $115 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
31 | $84 | $219 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $137 | $343 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
25 | $105 | $297 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
21 | $144 | $301 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
18 | $46 | $88 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.5% high complexity
83.8% medium
7.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,546
Total received (2018-2024)
Avg $2,078/year across 7 years
Top 19% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
87
Companies
752
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,495 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$51 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,359
2023
$3,102
2022
$2,710
2021
$1,006
2020
$490
2019
$2,268
2018
$1,611
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$343
AstraZeneca Pharmaceuticals LP
$254
Eisai Inc.
$185
Incyte Corporation
$174
ABBVIE INC.
$145
Merck Sharp & Dohme LLC
$143
Daiichi Sankyo Inc.
$135
Gilead Sciences, Inc.
$127
Janssen Biotech, Inc.
$112
Genmab U.S., Inc.
$101
Regeneron Healthcare Solutions, Inc.
$93
Celgene Corporation
$92
Takeda Pharmaceuticals U.S.A., Inc.
$89
Bayer Healthcare Pharmaceuticals Inc.
$77
Astellas Pharma US Inc
$73
TerSera Therapeutics LLC
$73
E.R. Squibb & Sons, L.L.C.
$70
GENZYME CORPORATION
$69
EMD Serono, Inc.
$64
SOBI, INC
$61
PFIZER INC.
$60
Mirati Therapeutics, Inc.
$56
ARRAY BIOPHARMA INC
$56
Stemline Therapeutics Inc.
$55
Myriad Genetic Laboratories, Inc.
$46
Exelixis Inc.
$46
Lilly USA, LLC
$44
BeiGene USA, Inc.
$43
Acrotech Biopharma Inc.
$40
GlaxoSmithKline, LLC.
$39
Aveo Pharmaceuticals, Inc.
$38
Genentech USA, Inc.
$38
PUMA BIOTECHNOLOGY, INC.
$37
Karyopharm Therapeutics Inc.
$32
Kite Pharma, Inc.
$25
MorphoSys, US Inc.
$24
Kyowa Kirin, Inc.
$24
Pharmacosmos Therapeutics Inc.
$23
Ipsen Biopharmaceuticals, Inc
$21
Apellis Pharmaceuticals, Inc.
$21
Alexion Pharmaceuticals, Inc.
$20
RECORDATI_RARE_DISEASES_INC.
$18
SERVIER PHARMACEUTICALS LLC
$16
Rigel Pharmaceuticals, Inc.
$15
JAZZ PHARMACEUTICALS INC.
$15
Secura Bio, Inc.
$15
ADC Therapeutics America, Inc.
$14
Top 3 companies account for 23.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,172
E.R. Squibb & Sons, L.L.C.
$1,018
PFIZER INC.
$850
AstraZeneca Pharmaceuticals LP
$769
Genentech USA, Inc.
$608
Janssen Biotech, Inc.
$557
Incyte Corporation
$556
Daiichi Sankyo Inc.
$438
Amgen Inc.
$436
Astellas Pharma US Inc
$406
Merck Sharp & Dohme Corporation
$362
GENZYME CORPORATION
$362
Merck Sharp & Dohme LLC
$357
Takeda Pharmaceuticals U.S.A., Inc.
$333
Celgene Corporation
$303
ABBVIE INC.
$286
Lilly USA, LLC
$284
Eisai Inc.
$273
Genmab U.S., Inc.
$263
Pharmacyclics LLC, An AbbVie Company
$249
Gilead Sciences, Inc.
$226
GlaxoSmithKline, LLC.
$178
EISAI INC.
$176
TerSera Therapeutics LLC
$172
Regeneron Healthcare Solutions, Inc.
$163
Kite Pharma, Inc.
$154
TESARO, Inc.
$153
MorphoSys, US Inc.
$152
ARRAY BIOPHARMA INC
$142
Seagen Inc.
$142
EMD Serono, Inc.
$135
Pharmacosmos Therapeutics Inc.
$133
Bayer Healthcare Pharmaceuticals Inc.
$130
Bayer HealthCare Pharmaceuticals Inc.
$122
Mirati Therapeutics, Inc.
$111
Exelixis Inc.
$108
Karyopharm Therapeutics Inc.
$99
Stemline Therapeutics Inc.
$99
Foundation Medicine, Inc.
$98
AbbVie, Inc.
$96
Pharmacyclics LLC, an AbbVie Company
$92
Janssen Pharmaceuticals, Inc
$85
Puma Biotechnology, Inc.
$84
Taiho Oncology, Inc.
$82
Myovant Sciences Inc.
$81
Boehringer Ingelheim Pharmaceuticals, Inc.
$81
PUMA BIOTECHNOLOGY, INC.
$73
Mylan Institutional Inc.
$67
Apellis Pharmaceuticals, Inc.
$66
Alexion Pharmaceuticals, Inc.
$66
SOBI, INC
$61
Acrotech Biopharma Inc.
$57
JAZZ PHARMACEUTICALS INC.
$56
Myriad Genetic Laboratories, Inc.
$46
Clovis Oncology, Inc.
$45
Spectrum Pharmaceuticals Inc.
$43
BeiGene USA, Inc.
$43
PharmaEssentia USA Corporation
$41
Acrotech Biopharma LLC
$40
Aveo Pharmaceuticals, Inc.
$38
Helsinn Therapeutics (U.S.), Inc.
$37
Deciphera Pharmaceuticals Inc.
$35
Rigel Pharmaceuticals, Inc.
$33
Prometheus Laboratories Inc.
$33
AbbVie Inc.
$33
Heron Therapeutics, Inc.
$31
Fortovia Therapeutics, Inc.
$31
Blueprint Medicines Corporation
$29
ImmunoGen, Inc.
$29
Sumitomo Pharma America, Inc.
$27
G1 Therapeutics, Inc.
$24
Kyowa Kirin, Inc.
$24
Ipsen Biopharmaceuticals, Inc
$21
INSYS Therapeutics Inc
$21
Array BioPharma Inc.
$21
SANOFI-AVENTIS U.S. LLC
$20
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$18
RECORDATI_RARE_DISEASES_INC.
$18
Sobi, Inc
$17
AMAG Pharmaceuticals, Inc.
$17
Dova Pharmaceuticals
$17
Seattle Genetics, Inc.
$16
Agios Pharmaceuticals, Inc.
$16
SERVIER PHARMACEUTICALS LLC
$16
Secura Bio, Inc.
$15
ADC Therapeutics America, Inc.
$14
MEDIVATION FIELD SOLUTIONS LLC
$13
Top 3 companies account for 20.9% of all-time payments
Associated products mentioned in payments ›
6 · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · Aliqopa · Avastin · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · FASLODEX · FERAHEME · FOLOTYN · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · FULPHILA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Perjeta · Polivy · Pomalyst · Poteligeo · Proleukin · QINLOCK · REBLOZYL · RELISTOR · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SPRYCEL · SUSTOL · SUTENT · SYLVANT · SYNAGIS · SYNDROS · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tivdak · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vitrakvi · Voranigo · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
273
Per 100K population
42.3
County median income
$111,951
Nearest hospital
ST MARY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Reilly is a mixed practice specialist, with above-average Medicare volume (top 12% in PA), with low-engagement industry engagement in the top 19% of PA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Reilly experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Reilly performed 20,820 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reilly receive payments from pharmaceutical companies?
Yes. Dr. Reilly received a total of $14,546 from 87 companies across 752 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reilly's costs compare to other hematology & oncology specialists in Langhorne?
Dr. Reilly's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reilly) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Langhorne
Browse hematology & oncology specialists in Langhorne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology